Compugen Provides Biosite with Option on Troponin Variant Biomarker | GenomeWeb
NEW YORK (GenomeWeb News) – Compugen said today that it had discovered and experimentally verified a variant of the Troponin I biomarker, and that it has granted an option to Biosite to develop the biomarker for immunoassay diagnostic products.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.